A recent study has identified that FXR participates in ACE2 expression in multiple tissues that are affected by COVID-19, and demonstrated that approved FXR inhibitors including z-guggulsterone and ursodeoxycholic acid downregulate ACE2 expression and reduced susceptibility to SARS-CoV-2 infection in lung, cholangiocyte and gut organoids (Brevini et al., 2021). The gene discussed is NR1H4; the disease is COVID-19.